MBIO Mustang Bio Inc.

4.17
+0.06  (+1%)
Previous Close 4.11
Open 4.12
Price To Book 2.35
Market Cap 168,616,267
Shares 40,472,437
Volume 62,951
Short Ratio
Av. Daily Volume 277,292

NewsSee all news

  1. Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution

    BOTHELL, Wash., Sept. 3, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 COH next readout due 4Q 2019. Phase 1/2 MBIO trial to commence 4Q 2019.
MB-102
Acute myeloid leukemia
Phase 1 readout due 2019.
MB-101
Glioblastoma
Phase 1 trial initiation announced October 30, 2018.
CAR-T therapy
HER2-positive breast cancer
Phase 1/2 trial ongoing. Initial data noted in NEJM.
MB-107
X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 initial data due 2019.
MB-106
B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 trial to be initiated late 2019 or 2020.
MB-104
Multiple myeloma
Phase 1 trial ongoing.
MB-103
HER2-Positive Breast Cancer with Brain Metastases

Latest News

  1. Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution

    BOTHELL, Wash., Sept. 3, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that